Literature DB >> 24723557

Fibrin-targeted magnetic resonance imaging allows in vivo quantification of thrombus fibrin content and identifies thrombi amenable for thrombolysis.

Marcelo E Andia1, Prakash Saha1, Julia Jenkins1, Bijan Modarai1, Andrea J Wiethoff1, Alkystis Phinikaridou1, Steven P Grover1, Ashish S Patel1, Tobias Schaeffter1, Alberto Smith1, Rene M Botnar1.   

Abstract

OBJECTIVE: Deep venous thrombosis is a major health problem. Thrombolytic therapies are effective in recanalizing the veins and preventing post-thrombotic complications, but there is no consensus on selection criteria. The aim of this study was to investigate a fibrin-specific MRI contrast agent (EP-2104R) for the accurate quantification of thrombus' fibrin content in vivo and for the identification of thrombus suitable for thrombolysis. APPROACH AND
RESULTS: Venous thrombosis was induced in the inferior vena cava of 8- to 10-week-old male BALB/C mice and MRI performed 2, 4, 7, 10, 14, and 21 days later. Eighteen mice were scanned at each time point pre and 2 hours post injection of EP-2104R (8.0 μmol/kg) with 12 mice at each time point used to correlate fibrin contrast uptake with thrombus' histological stage and fibrin content. Six mice at each time point were immediately subjected to intravascular thrombolytic therapy (10 mg/kg of tissue-type plasminogen activator). Mice were imaged to assess response to lytic therapy 24 hours after thrombolytic treatment. Two mice at each time point were scanned post injection of 0.2 mmol/kg of Gd-DTPA (gadolinium with diethylenetriaminepentacetate, Magnevist, Schering AG, Berlin, Germany) for control purpose. Contrast uptake was correlated positively with the fibrin content of the thrombus measured by Western blotting (R(2)=0.889; P<0.001). Thrombus relaxation rate (R1) post contrast and the change in visualized thrombus size on late gadolinium enhancement inversion recovery MRI pre-EP-2104R and post-EP-2104R injection were the best predictors for successful thrombolysis (area under the curve, 0.989 [95% confidence interval, 0.97-1.00] and 0.994 [95% confidence interval, 0.98-1.00] respectively).
CONCLUSIONS: MRI with a fibrin-specific contrast agent accurately estimates thrombus fibrin content in vivo and identifies thrombi that are amenable for thrombolysis.
© 2014 American Heart Association, Inc.

Entities:  

Keywords:  fibrin; magnetic resonance imaging; molecular imaging; thrombolytic therapy; venous thrombosis

Mesh:

Substances:

Year:  2014        PMID: 24723557      PMCID: PMC4195984          DOI: 10.1161/ATVBAHA.113.302931

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  39 in total

1.  Short- and long-term results after thrombolytic treatment of deep venous thrombosis.

Authors:  J Schweizer; W Kirch; R Koch; H Elix; G Hellner; L Forkmann; A Graf
Journal:  J Am Coll Cardiol       Date:  2000-10       Impact factor: 24.094

Review 2.  Clinical practice. Chronic venous insufficiency and varicose veins.

Authors:  Seshadri Raju; Peter Neglén
Journal:  N Engl J Med       Date:  2009-05-28       Impact factor: 91.245

3.  Molecular magnetic resonance imaging of deep vein thrombosis using a fibrin-targeted contrast agent: a feasibility study.

Authors:  Marcus Katoh; Patrick Haage; Andrea J Wiethoff; Rolf W Günther; Arno Bücker; Josef Tacke; Elmar Spuentrup
Journal:  Invest Radiol       Date:  2009-03       Impact factor: 6.016

4.  3D T(1)-mapping for the characterization of deep vein thrombosis.

Authors:  Ulrike Blume; James Orbell; Matthew Waltham; Alberto Smith; Reza Razavi; Tobias Schaeffter
Journal:  MAGMA       Date:  2009-11-28       Impact factor: 2.310

5.  Evaluation of the fibrin binding profile of two anti-fibrin monoclonal antibodies.

Authors:  S Raut; P J Gaffney
Journal:  Thromb Haemost       Date:  1996-07       Impact factor: 5.249

6.  Catheter-directed thrombolysis for lower extremity deep venous thrombosis: report of a national multicenter registry.

Authors:  M W Mewissen; G R Seabrook; M H Meissner; J Cynamon; N Labropoulos; S H Haughton
Journal:  Radiology       Date:  1999-04       Impact factor: 11.105

7.  Molecular magnetic resonance imaging of coronary thrombosis and pulmonary emboli with a novel fibrin-targeted contrast agent.

Authors:  Elmar Spuentrup; Arno Buecker; Marcus Katoh; Andrea J Wiethoff; Edward C Parsons; Rene M Botnar; Robert M Weisskoff; Philip B Graham; Warren J Manning; Rolf W Günther
Journal:  Circulation       Date:  2005-02-28       Impact factor: 29.690

8.  Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

Authors:  Clive Kearon; Susan R Kahn; Giancarlo Agnelli; Samuel Goldhaber; Gary E Raskob; Anthony J Comerota
Journal:  Chest       Date:  2008-06       Impact factor: 9.410

9.  MR imaging of thrombi using EP-2104R, a fibrin-specific contrast agent: initial results in patients.

Authors:  Elmar Spuentrup; Rene M Botnar; Andrea J Wiethoff; Tareq Ibrahim; Sebastian Kelle; Marcus Katoh; Murat Ozgun; Eike Nagel; Josef Vymazal; Phil B Graham; Rolf W Günther; David Maintz
Journal:  Eur Radiol       Date:  2008-04-19       Impact factor: 5.315

10.  Thrombus imaging with fibrin-specific gadolinium-based MR contrast agent EP-2104R: results of a phase II clinical study of feasibility.

Authors:  Josef Vymazal; Elmar Spuentrup; Gerardo Cardenas-Molina; Andrea J Wiethoff; Michael G Hartmann; Peter Caravan; Edward C Parsons
Journal:  Invest Radiol       Date:  2009-11       Impact factor: 6.016

View more
  18 in total

1.  Multisite Thrombus Imaging and Fibrin Content Estimation With a Single Whole-Body PET Scan in Rats.

Authors:  Francesco Blasi; Bruno L Oliveira; Tyson A Rietz; Nicholas J Rotile; Pratap C Naha; David P Cormode; David Izquierdo-Garcia; Ciprian Catana; Peter Caravan
Journal:  Arterioscler Thromb Vasc Biol       Date:  2015-08-13       Impact factor: 8.311

2.  In Vivo Molecular Characterization of Abdominal Aortic Aneurysms Using Fibrin-Specific Magnetic Resonance Imaging.

Authors:  René M Botnar; Julia Brangsch; Carolin Reimann; Christian H P Janssen; Reza Razavi; Bernd Hamm; Marcus R Makowski
Journal:  J Am Heart Assoc       Date:  2018-05-30       Impact factor: 5.501

3.  Radiation Dosimetry of the Fibrin-Binding Probe ⁶⁴Cu-FBP8 and Its Feasibility for PET Imaging of Deep Vein Thrombosis and Pulmonary Embolism in Rats.

Authors:  Francesco Blasi; Bruno L Oliveira; Tyson A Rietz; Nicholas J Rotile; Helen Day; Pratap C Naha; David P Cormode; David Izquierdo-Garcia; Ciprian Catana; Peter Caravan
Journal:  J Nucl Med       Date:  2015-05-14       Impact factor: 10.057

4.  Primary hydatid cyst in the adrenal gland.

Authors:  Afshin Mohammadi; Mohammad Ghasemi-Rad; Rahmi Oklu
Journal:  BMJ Case Rep       Date:  2014-10-23

Review 5.  Targeting Oxidative Stress Using Nanoparticles as a Theranostic Strategy for Cardiovascular Diseases.

Authors:  Kye S Kim; Chul Gyu Song; Peter M Kang
Journal:  Antioxid Redox Signal       Date:  2018-01-30       Impact factor: 8.401

Review 6.  Molecular magnetic resonance imaging of atherosclerotic vessel wall disease.

Authors:  Dominik Nörenberg; Hans U Ebersberger; Gerd Diederichs; Bernd Hamm; René M Botnar; Marcus R Makowski
Journal:  Eur Radiol       Date:  2015-07-03       Impact factor: 5.315

Review 7.  Fibrinogen and Fibrin in Hemostasis and Thrombosis.

Authors:  Sravya Kattula; James R Byrnes; Alisa S Wolberg
Journal:  Arterioscler Thromb Vasc Biol       Date:  2017-03       Impact factor: 8.311

8.  Imaging Tropoelastin in Atherosclerosis.

Authors:  Raphaël Duivenvoorden; Willem J M Mulder
Journal:  Circ Cardiovasc Imaging       Date:  2018-08       Impact factor: 7.792

Review 9.  State-of-the-Art Imaging for the Evaluation of Pulmonary Embolism.

Authors:  Leonid Roshkovan; Harold Litt
Journal:  Curr Treat Options Cardiovasc Med       Date:  2018-08-07

Review 10.  Peptide-based fibrin-targeting probes for thrombus imaging.

Authors:  Bruno L Oliveira; Peter Caravan
Journal:  Dalton Trans       Date:  2017-10-31       Impact factor: 4.390

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.